The continuing search for impactful chemotherapies in HRPC

In March this year it was announced that the combination of bevacizumab (Avastin) with docetaxel and prednisone had no benficial impact (in a large Phase III trial) on the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. There are, naturally, hopes that the outcome might be different if one adds a third drug into the mix. … READ MORE …

New data from two studies on adjuvant radiation and thalidomide post-surgery

Biochemical recurrence after first-line treatment for localized prostate cancer affects some 30 to 40 percent of prostate cancer patients. Two articles to be published in the March 2009 issue of The Journal of Urology provide interesting new data on the treatment of men who have either failed first-line surgical treatment or are at high risk for such failure. … READ MORE …